Brian Jamieson, FCA

Non-Executive Chairman

Brian Jamieson was Chief Executive of Minter Ellison Melbourne and a partner of the Minter Ellison Revenue Group from 2002 to 2005, when he retired as Chief Executive. Prior to joining Minter Ellison, he was Executive Officer at KPMG Australia from 1998 to 2000, Managing Partner of KPMG Melbourne and Southern Regions from 1993 to 1998 and Chairman of KPMG Melbourne from 2001 to 2002. Mr Jamieson was also a KPMG Board Member in Australia and a member of the United States Management Committee. He has over 30 years of experience providing advice and audit services to a diverse range of public and large private companies and is a fellow of the Institute of Chartered Accountants in Australia.

Additional Current Directorships

  • Chairman, Sigma Pharmaceuticals Limited
  • Non-Executive Director, Tatts Group Limited
  • Non-Executive Director, OZ Minerals Limited
  • Director and Treasurer, Bionics Institute

 

Silviu Itescu - MBBS, FRACP, FACP, FTSE

Chief Executive Officer and Managing Director

Prior to founding Mesoblast in 2004, Professor Silviu Itescu established an outstanding international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. He is an active faculty member of Melbourne and Monash universities in Australia and was previously a faculty member of Columbia University in New York. Under his leadership, Mesoblast received the 2011 Deals of Distinction™ Award from The Licensing Executives Society (United States and Canada) Inc. for its alliance with Cephalon, Inc., later acquired by Teva Pharmaceutical Industries Ltd, and the 2013 Scrip Award for Financing Deal of the Year. In 2011, Professor Itescu was named BioSpectrum Asia Person of the Year. In 2013 he received the inaugural Key Innovator Award from the Vatican's Pontifical Council for Culture for his leadership and ingenuity in translational science and clinical medicine in relation to adult stem cell therapy. Professor Itescu has consulted for various international pharmaceutical companies, has been an adviser to biotechnology and health care investor groups, and has served on the Board of Directors of a number of publicly-listed life sciences companies.

 

William M. Burns, BA

Non-Executive Director

William (Bill) M. Burns has spent his entire career to date in two companies, the Beecham Group and F. Hoffmann-La Roche Ltd. He was Chief Executive Officer of Roche Pharmaceuticals from 2001 to 2009, when he joined the Board of F. Hoffmann-La Roche until he retired in 2014. His responsibilities spanned from research to commercialization. Mr Burns has also served on the Board of Directors of Genentech, and as a Director of Chugai Pharmaceutical Co. Additional roles have included as Chairman of biologic companies Okairos, acquired in 2013 by GlaxoSmithKline, and Crucell, acquired in 2011 by Johnson & Johnson. He chaired the Swiss Research Trade Association for several years and represented the company on the European and International Trade Associations Management Boards. He also supports the Wellcome Trust New Technologies group and is a member of the Oncology Advisory Board of the Universities of Cologne/Bonn.

Additional Current Directorships

  • Chairman, Masters Speciality Pharma (UK)
  • Vice Chairman, Biotie Therapeutics (Finland)
  • Vice Chairman, Vestergaard- Frandsen (Switzerland)
  • Non-Executive Director, Shire (UK)

 

Donal O’Dwyer, BE, MBA

Non-Executive Director

Donal O’Dwyer has over 25 years of experience as a senior executive in the global cardiovascular and medical devices industries. From 1996 to 2003, he worked for Cordis Cardiology, the cardiology division of Johnson & Johnson’s Cordis Corporation, initially as its President (Europe) and as its worldwide President from 2000. In his role, Mr O’Dwyer led Cordis through the launch of the revolutionary Cypher drug eluting coronary stent technology, and saw the company take over number one market share of coronary stents worldwide. Prior to joining Cordis, he worked for 12 years with Baxter Healthcare, rising from plant manager in Ireland to President of the Cardiovascular Group, Europe (now Edwards Lifesciences). Mr O’Dwyer is a qualified civil engineer and has an MBA.

Additional Current Directorships

  • Non-Executive Director, Cochlear Limited
  • Chairman and Non-Executive Director, Atcor Medical Holdings Limited
  • Chairman, Endoluminal Sciences Pty Ltd
  • Non-Executive Director, Fisher & Paykel Healthcare

 

Eric A. Rose, MD

Non-Executive Director

Eric Rose is a world leader in cardiovascular medicine. He is currently Chairman and CEO of SIGA Technologies and Executive Vice President, Life Sciences, at MacAndrews & Forbes, Inc., the holding company of Ronald O. Perelman. From 2008 through 2012, Dr Rose served as the Edmond A. Guggenheim Professor and Chairman of the Department of Health Evidence and Policy at the Mount Sinai School of Medicine, which has an extensive portfolio of research focused on evaluation of complex medical technologies in cardiovascular disease, cancer, diabetes mellitus, and neurologic disease. From 1994 through 2007, Dr Rose served as Chairman of the Department of Surgery and Surgeon-in-Chief of the Columbia Presbyterian Center of New York Presbyterian Hospital. From 1982 to 1992, he led the Columbia Presbyterian heart transplantation program, during which time it became the most active program in the United States. Dr Rose pioneered heart transplantation in children, performing the first successful pediatric heart transplant in 1984. He has investigated many alternatives to heart transplantation, including cross species transplantation and man-made heart pumps and is also Chairman of the Board of Circulite, Inc., a developer of advanced left ventricular assist devices. Dr Rose has authored or co-authored more than 300 scientific publications and has received more than $25 million in National Institutes of Health support for his research.

Additional Current Directorships

  • Chairman, SIGA Technologies
  • Chairman, Circulite Inc.

 

Michael Spooner, BCom, ACA, MAICD

Non-Executive Director

Michael Spooner is a well-known and respected business leader. He has an extensive network of relationships with investment firms and business communities across the globe, having spent the majority of the past 25 years living and working internationally. Mr Spooner consults for a number of listed and unlisted companies based in Australia and the United States. Most recently, he was a non-executive Director of Hawaii Biotech Inc., a specialty developer of vaccines from 2010 to 2011. In 2009, Mr Spooner was appointed Chairman of BiVACOR, a total artificial heart company. He was also a non-executive Director of Peplin Inc., a dermatology-focused skin cancer company from 2004 until the company was sold in 2009 for over $300 million. Previously, Mr Spooner was the Chairman of Mesoblast Limited from its initial listing in 2004 until 2007 and Managing Director & CEO of Ventracor Limited where he led the transformation of a small Australia-listed life sciences company into the second highest performing stock on the S&P/ASX 200 Index. He was also a Principal Partner and Director of Consulting Services with PricewaterhouseCoopers (Coopers & Lybrand) in Hong Kong for several years.

 

Ben-Zion Weiner, BSc, MSc, PhD

Non-Executive Director

Ben-Zion Weiner was head of global research and development at Teva Pharmaceutical Industries Ltd for over three decades, including as Chief R&D Officer and a member of the Teva Executive Committee. He directly oversaw all pharmaceutical R&D and innovative branded product pipeline development. Dr Weiner has been responsible for the development of hundreds of generic products for the United States, European and other markets. In parallel, he has been responsible for the development and regulatory approval of Teva’s innovative product portfolio. Dr Weiner has twice been the recipient of the Rothschild prize for innovation, including for the commercialization of Copaxone in the treatment of multiple sclerosis. He retired from Teva at the end of 2012. Dr Weiner is no longer affiliated with Teva and continues to serve on the Mesoblast Board as an independent non-executive Director.

 

Charlie Harrison – BA, LLB (Hons)

Company Secretary

Charlie Harrison joined Mesoblast as a legal counsel in 2013. He was previously a senior associate at the international law firm Allens, working in their Hong Kong and Melbourne offices for nine years as a corporate lawyer. Mr Harrison has an Arts/Law degree from the University of Melbourne. He was appointed Company Secretary in September 2014.